Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Outlook Therapeutics (OTLK) Share-based Compensation (2016 - 2025)

Outlook Therapeutics (OTLK) has disclosed Share-based Compensation for 8 consecutive years, with $881150.0 as the latest value for Q4 2025.

  • Quarterly Share-based Compensation fell 76.01% to $881150.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $6.1 million through Dec 2025, up 7.22% year-over-year, with the annual reading at $8.9 million for FY2025, 65.23% up from the prior year.
  • Share-based Compensation for Q4 2025 was $881150.0 at Outlook Therapeutics, down from $1.9 million in the prior quarter.
  • The five-year high for Share-based Compensation was $3.7 million in Q4 2024, with the low at $881150.0 in Q4 2025.